Arbutus Biopharma Corp reports results for the quarter ended in December - Earnings Summary

Arbutus Biopharma

03/03/2023 19:01

* Arbutus Biopharma Corp  ABUS.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 13 cents per share.
    * Revenue rose 94.8% to $6.25 million from a year ago;
analysts
expected $6.18 million. 
    * Arbutus Biopharma Corp's reported EPS for the quarter was
a loss
of 14 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Arbutus Biopharma Corp shares had risen by 20.6% this
quarter.
    * The company reported a quarterly loss of $21.93 million.
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 3
at 07:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.13          -0.14          Missed
 Sep. 30 2022      -0.13          -0.12          Beat
 Jun. 30 2022      -0.13          -0.10          Beat
 Mar. 31 2022      -0.16          -0.11          Beat